MADRIGAL PHARMACEUTICALS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$269.49 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-06.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2023-11-06
- MADRIGAL PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$218.24M, a 3729.49% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was $6.01M.
- MADRIGAL PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was -$9.80M, a 149.11% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was $19.95M.
- MADRIGAL PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $295.28M.
- MADRIGAL PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was -$17.73M, a 342.71% decline from fiscal 2020.
- MADRIGAL PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was $7.31M.
- MADRIGAL PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was -$10.68M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$269.49M 10-Q · filed 2023-11-06 | |||
| 2023-06-30 | -$254.35M 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | -$218.24M 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $295.28M 10-K/A · filed 2023-03-03 | |||
| 2022-09-30 | $23.07M 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | $17.00M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | $6.01M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | -$17.73M 10-K/A · filed 2023-03-03 | |||
| 2021-09-30 | -$4.83M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | -$20.46M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | -$9.80M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $7.31M 10-K/A · filed 2023-03-03 | |||
| 2020-09-30 | $62.42M 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $15.17M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $19.95M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$10.68M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $32.11M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $15.13M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$9.89M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | -$91.25M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | -$110.58M 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | $116.23M 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | -$110.50M 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | $129.48M 10-K · filed 2020-02-26 | |||
| 2017-09-30 | -$6.18M 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | $15.65M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $18.84M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |